Senores Pharmaceuticals Reports Q3 FY26 Revenue of Rs. 175 Cr, up 64% YoY
Filing Summary
Senores Pharmaceuticals Limited announced its unaudited financial results for Q3 FY26, reporting a consolidated total income of Rs. 175 crores, marking a 64% increase year-over-year. The company’s EBITDA reached Rs. 54 crores, with a profit after tax of Rs. 34 crores, reflecting an increase of 86% and 105%, respectively. The company also highlighted its operational achievements, including the completion of a 75% stake acquisition in Apnar Pharmaceuticals. Senores continues to expand its product portfolio in regulated and emerging markets, with significant growth in its branded generics business.
Senores Pharmaceuticals Limited has released its unaudited financial results for the third quarter of the fiscal year 2026. The company reported a consolidated total income of Rs. 175 crores, representing a 64% increase compared to the same period last year. The results were approved by the Board of Directors on January 20, 2026. The financial performance for the nine months ending December 31, 2025, also showed significant growth, with total income reaching Rs. 474 crores, a 65% increase year-over-year.
In terms of profitability, Senores Pharmaceuticals reported an EBITDA of Rs. 54 crores for Q3 FY26, which is an 86% increase from the previous year. The profit after tax for the quarter was Rs. 34 crores, reflecting a 105% rise. For the nine-month period, EBITDA was Rs. 138 crores, and profit after tax was Rs. 85 crores, marking increases of 87% and 110%, respectively. The company’s cash flow from operations for the quarter stood at approximately Rs. 19 crores, with a nine-month total of Rs. 51 crores.
Operationally, Senores Pharmaceuticals has made strides in both regulated and emerging markets. The company reported revenue of Rs. 112.7 crores from regulated markets for Q3 FY26, a 60.5% increase year-over-year, with an EBITDA margin of 40%. In emerging markets, revenue for the quarter was Rs. 38.4 crores, with an EBITDA margin of 13%. The company has a portfolio of 46 approved ANDAs covering 137 strengths, with 22 additional ANDAs under development.
The acquisition of Apnar Pharmaceuticals is a key milestone for Senores. The company completed the first phase of acquiring a 75% stake, with the remaining 25% expected to be finalized by Q2 FY27. This acquisition includes five approved ANDAs, with three set to launch in Q4 FY26. The integration of Apnar Pharmaceuticals is progressing faster than initially planned.
Senores Pharmaceuticals is actively involved in expanding its presence in both regulated and emerging markets. The company has 450 approved products and 858 products under registration, with a presence in over 40 countries. The company’s manufacturing facilities in the US and India are approved by various regulatory bodies, including the USFDA and WHO-GMP.
Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company focused on developing and manufacturing a wide range of pharmaceutical products for regulated and emerging markets. The company has a strong R&D capability with four sites, including one in the USA and three in India, supporting its diverse product portfolio.